Among Patients With CADASIL, Shunting
Unrelated to Migraine, Says Study
BY JOHN R. BELL
Elsevier Global Medical News
BOSTON (EGMN) - The presence of migraine with aura does not increase the likelihood of left-to-right shunting in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, according to findings presented in a poster at the annual meeting of the American Academy of Neurology.
Dr. Christian Stapf of Hopital Lariboisiere, Paris, and colleagues assessed 55 consecutive patients from a prospective national referral cohort who had cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Investigators screened the study participants for cardiac left-to-right shunting.
Of the total 55 patients, 15 (27%) had migraine with aura, and 17 (31%) had right-to-left shunting caused by patent foramen ovale (PFO). Mean patient age was 41 years, and 56% were men.
There was no statistically significant difference in the frequency of right-to-left shunting in the 6 patients with migraine and aura and the 11 patients without migraine and aura, judging from findings of the univariate analysis.
Patient age, sex, and stroke history showed no significant association with the migraine and aura diagnosis or with right-to-left shunting, Dr. Stapf and colleagues reported.
© Copyright 2007 Elsevier Global Medical News. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the copyright owner. No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, through negligence or otherwise or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, the Publisher recommends that independent verification f diagnoses and drug dosages should be made. Opinions expressed in this publication are those of the original authors and do not necessarily reflect those of the publisher, the sponsor, or the editors, Elsevier assumes no liability for any material published herein.
Dispensing errors have been reported between TOPAMAX® (topiramate) Tablets and TOPROL-XL® (metoprolol succinate) extended-release Tablets.
Please be sure to check your tablets to ensure you are taking the right medicine.
*TOPROL-XL is a registered trademark of the AstraZeneca group of companies.
TOPAMAX Tablets and TOPAMAX Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX in the acute treatment of migraine headache has not been studied.
TOPAMAX is contraindicated in patients with a history of hypersensitivity to any component of this product.
IMPORTANT SAFETY INFORMATION
TOPAMAX has been associated with serious adverse events, including:
- Hyperchloremic, non-anion gap metabolic acidosis - lowering of bicarbonate levels in the blood. Measurement of baseline and periodic serum bicarbonate is recommended.
- Acute myopia and secondary angle-closure glaucoma - patients should be cautioned to seek medical attention if they experience blurred vision or ocular pain.
- Oligohidrosis and hyperthermia - decreased sweating and increased body temperature, especially in hot weather. The majority of reports have been in children.
- Cognitive/psychiatric side effects including cognitive dysfunction, psychiatric/behavioral disturbances, including suicidal thoughts or behavior, and somnolence and fatigue.
Most common adverse events associated with TOPAMAX 100 mg vs placebo were: paresthesia, 51% vs 6%; anorexia,* 15% vs 6%; fatigue, 15% vs 11%; nausea, 13% vs 8%; diarrhea, 11% vs 4%; weight decrease, 9% vs 1%; taste alteration, 8% vs 1%.
The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX.
Patients should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation.
*Anorexia is defined as loss of appetite
Please see full U.S. Prescribing Information
